Valeant divests generic Benzaclin and Efudex to Mylan

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to Mylan Inc. (Nasdaq: MYL).

This action was required under the consent order issued by the Federal Trade Commission (FTC) as part of the acquisition of Dermik, a dermatology unit of Sanofi (EURONEXT: SAN and NYSE: SNY), which was completed in December 2011. 

Source:

Valeant Pharmaceuticals International, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Decreased hippocampal activity linked to worse PTSD symptoms